Bravecto

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued / amended on	Product Information affected[2]	Summary[3]
IB/0055	B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation	09/02/2022	n/a		n/a
II/0051	C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	09/12/2021	01/02/2022	SPC and PL	The European Commission amended the decision granting the marketing authorisation to add a new therapeutic indication for Bravecto chewable tablets for dogs: for reduction of the risk of infection with Babesia canis canis via transmission by Dermacentor reticulatus for up to 12 weeks. The effect is indirect due to product's activity against the vector.
II/0053	B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range	09/12/2021	n/a		
IB/0052	C.I.3.z - Change(s) in the SPC, Labelling or PL of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority that does not require additional assessment	08/10/2021	01/02/2022	SPC and PL	The Agency accepted the variation to update SPC section 4.6 Adverse reactions and corresponding section 6 of the package leaflet for Bravecto spot-on solution for cats following a PSUR assessment.
IB/0050	B.IV.1.z - Change of a measuring or administration device - Other variation	11/06/2021	01/02/2022	SPC, Labelling and PL	The Agency accepted the variation to add gloves into the carton boxes of the medicinal product.

[1] Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.
[2] SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
[3] Since October 2019 summary information is no longer published for variations that do not impact upon the product information

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

IB/0049/G	This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	19/03/2021	n/a		n/a
IG/1331	A.7 - Administrative change - Deletion of manufacturing sites	04/02/2021	01/02/2022	Annex II and PL	The Agency accepted the variation to delete a manufacturing site responsible for batch release.
IB/0046/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	25/09/2020	n/a		n/a
IG/1276	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	11/08/2020	n/a		n/a
IG/1241	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	17/06/2020	09/12/2020	Annex II and PL	The Agency accepted the variation to change the name of a manufacturing site responsible for batch release.
II/0042	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	23/04/2020	09/12/2020	SPC and PL	The Agency accepted the variation to lower the minimum age of target animals from 11 weeks to 9 weeks for Bravecto spot-on solution for cats.
IB/0041	C.I.3.z - Change(s) in the SPC, Labelling or PL of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority that does not require additional assessment	21/02/2020	09/12/2020	SPC and PL	The Agency accepted the variation to include additional warning sentences in the SPC and package leaflet following assessment of a PSUR.
WS/1764	This was an application for a variation following a worksharing procedure according to Article 20 of	20/02/2020	n/a		n/a

	Commission Regulation (EC) No 1234/2008. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
IG/1208	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	17/02/2020	n/a		n/a
II/0039	B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range	23/01/2020	n/a		n/a
WS/1721/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF	05/12/2019	n/a		n/a
IB/0037/G	This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol	04/12/2019	09/12/2020	SPC	The Agency accepted the group of variations, including the change to extend the shelf-life of the finished product (spot-on solution) from 24 months to 36 months, applicable to the 250mg, 500 mg, 1000mg and 1400mg strengths.

II/0036	C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	12/09/2019	18/10/2019	SPC, Labelling and PL	The European Commission amended the decision granting the marketing authorisation to add a new therapeutic indication: for the treatment of demodicosis caused by Demodex canis in dogs. Additionally, the MAH is updating the labelling section for Bravecto spot-on solution for dogs and cats with regard to the information included on the pipette label.
II/0033/G	This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	12/09/2019	18/10/2019	SPC and PL	The European Commission amended the decision granting the marketing authorisation to add two new therapeutic indications: for the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation in dogs and for the treatment of infestations with ear mites (Otodectes cynotis) in cats. The third proposed indication, for the treatment of infestations with ear mites (Otodectes cynotis) in dogs, was withdrawn by the applicant during the procedure. Additionally, editorial changes are implemented in various languages to correct translation errors not detected in previous linguistic reviews.
II/0035/G	This was an application for a group of variations. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	17/04/2019	18/10/2019	SPC and PL	The Agency accepted the variation to update section 4.5 of the SPC of Bravecto chewable tablets for dogs, following the assessment of a PSUR. With this procedure, Annex IV is removed from the product information. The type II variation (scope C.I.4) was withdrawn by the MAH during the procedure.
IB/0034	B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation	22/02/2019	n/a		The Agency accepted the variation to introduce an alternative manufacturer of an excipient.
R/0028	Renewal of the marketing authorisation.	06/12/2018	05/02/2019	SPC, Annex II, Labelling and PL	The European Commission renewed the marketing authorisation for Bravecto.
IAIN/0032	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	17/12/2018	18/10/2019	Annex II and PL	The Agency accepted the variation to introduce an additional manufacturer for batch release.
II/0030/G	This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of	06/12/2018	n/a		The Agency accepted the group of variations to add a new manufacturing site for one of the active substances, to make minor changes to the manufacturing process of the intermediate and changes to the description of the manufacturing process of the active substance. Additionally, to delete a test for a component used in the manufacturing process, to widen the specification of one component used for the manufacture of the intermediate, to delete a non-significant parameter and change the specification of the primary packaging of the active

	the AS - Minor change to the restricted part of an ASMF B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				substance, and to extend the retest period of the active substance.
IG/1014	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	26/11/2018	n/a		The Agency accepted the variation to introduce a minor change in the manufacturing process of the finished products regarding the filling step.
IG/0967/G	This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system	26/07/2018	n/a		n/a
IA/0027	B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure	11/06/2018	n/a		The Agency accepted the variation to introduce a minor change to the analytical procedure for the testing of acetone.
IB/0026	C.I.4.z - Change(s) in the SPC, Labelling or package leaflet further to a veterinary PSUR	18/05/2018	05/02/2019	SPC, Annex II, Labelling and PL	The Agency accepted the variation to update the SPC following assessment of a PSUR.
IB/0025	B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	08/05/2018	n/a		The Agency accepted the variation to tighten the shelf life limit for dissolution assay.
IB/0024	B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation	01/03/2018	n/a		The Agency accepted the variation to change the specification parameters of an excipient.

IB/0023/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	21/12/2017	n/a		The Agency accepted the group of variations to process the changes in ASMF: change in the batch size of active substance and intermedia, change in the manufacturing process and change in the specification parameter.
IB/0022	C.I.4.z - Change(s) in the SPC, Labelling or package leaflet further to a veterinary PSUR	06/10/2017	19/03/2018	SPC and PL	The Agency accepted the variation to amend the product literature following assessment of a targeted PSUR.
IB/0021/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	11/08/2017	n/a		The Agency accepted the group of variations to change the manufacturing process of the active substance, to tighten the specification limits for the active substance and to make changes to the restricted part of the ASMF.
IAIN/0020	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	19/06/2017	n/a		The Agency accepted the variation to introduce a secondary packaging site for Bravecto spot-on solution in addition to the current packaging site.
IA/0019	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	02/05/2017	19/03/2018	SPC	The Agency accepted the variation to update the ATCVet code for the active substance fluralaner.
IB/0018	C.I.4.z - Change(s) in the SPC, Labelling or package leaflet further to a veterinary PSUR	16/03/2017	19/03/2018	SPC and PL	The Agency accepted the variation to amend the SPC under section 4.6 Adverse events and the package leaflet under section 6 with a new sentence, following a recommendation from CVMP.
II/0017/G	This was an application for a group of variations. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.a.1.b - Change in the manufacturer of AS or of a	16/03/2017	n/a		The Agency accepted the variation to add active substance manufacturers and to change the re-test period of the active substance.

	starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
IB/0016/G	This was an application for a group of variations. B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	22/12/2016	n/a		The Agency accepted the group of variations to change the specification parameters of an excipient and to change the specification parameters of the finished product.
IA/0015/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	13/10/2016	n/a		The Agency accepted the group of variations to introduce minor changes to the approved test procedures performed in the finished product release testing.

	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IG/0718/G	This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system	22/09/2016	n/a		n/a
IA/0013	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	08/09/2016	n/a		The Agency accepted the variation to introduce minor changes to an approved test procedure.
IB/0012/G	This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	27/07/2016	n/a		The Agency accepted the group of variations to introduce a number of changes to the ASMF for the active substance, fluralaner.
X/0005	Annex I_2.(d) Change or addition of a new pharmaceutical form	17/03/2016	17/05/2016	SPC, Labelling and PL	The European Commission amended the decision granting the marketing authorisation to add a new pharmaceutical form (spot-on solution) for dogs and a new target species (cats) for this spot-on formulation.
II/0010/G	This was an application for a group of variations. B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size	18/02/2016	n/a		The Agency accepted the group of variations to introduce new manufacturers and to change the batch size of the active substance.

	ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size				
IB/0008	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	11/11/2015	n/a		The Agency accepted the variation to increase the batch size range of the finished product.
IA/0009	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	06/11/2015	n/a		The Agency accepted the variation to introduce a minor change to an approved test procedure.
IA/0006	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	11/09/2015	17/05/2016	SPC, Labelling and PL	The Agency accepted the variation to register an alternative blister foil and lidding foil.
IG/0464	C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	20/08/2014	n/a		The Agency accepted the variation to implement the company's updated detailed description of the pharmacovigilance system (DDPS).
IA/0003	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	18/07/2014	n/a		The Agency accepted the variation to amend the dissolution assay test method.
IA/0002	B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	18/07/2014	n/a		The Agency accepted the variation to add the optional use of the medium blister cavity for the 112.5 mg and 250 mg chewable tablets.
IB/0001/G	This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	16/07/2014	n/a		The Agency accepted the variation to change the storage conditions of an intermediate, to extend the stability data of the starting materials, to reduce the storage re-test period, to extend the test intervals and to update the stability protocol for the active substance.